0002107396-26-000004.txt : 20260331 0002107396-26-000004.hdr.sgml : 20260331 20260331164501 ACCESSION NUMBER: 0002107396-26-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260331 DATE AS OF CHANGE: 20260331 EFFECTIVENESS DATE: 20260331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gilgamesh Pharma Inc. CENTRAL INDEX KEY: 0002107396 ORGANIZATION NAME: EIN: 393989868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-578605 FILM NUMBER: 26822874 BUSINESS ADDRESS: STREET 1: 113 UNIVERSITY PLACE, SUITE 1019 CITY: NEW YORK STATE: NY ZIP: 10003 BUSINESS PHONE: 929-723-4861 MAIL ADDRESS: STREET 1: 113 UNIVERSITY PLACE, SUITE 1019 CITY: NEW YORK STATE: NY ZIP: 10003 D 1 primary_doc.xml X0708 D LIVE 0002107396 Gilgamesh Pharma Inc. 113 UNIVERSITY PLACE, SUITE 1019 NEW YORK NY NEW YORK 10003 929-723-4861 DELAWARE None None Corporation true 2025 Jonathan Sporn 113 University Place, Suite 1019 New York NY NEW YORK 10003 Executive Officer Director Andrew Kruegel 113 University Place, Suite 1019 New York NY NEW YORK 10003 Executive Officer Director Amy Kruse 113 University Place, Suite 1019 New York NY NEW YORK 10003 Director Zia Huque 113 University Place, Suite 1019 New York NY NEW YORK 10003 Director Robert Berman 113 University Place, Suite 1019 New York NY NEW YORK 10003 Director Phil Skolnick 113 University Place, Suite 1019 New York NY NEW YORK 10003 Director Pharmaceuticals Decline to Disclose 06b false 2026-03-27 false true true Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert. false 50000 15000000 2250000 12750000 false 3 0 0 0 false Gilgamesh Pharma Inc. Jonathan Sporn /s/ Jonathan Sporn CEO 2026-03-31